Jeff Baxter
Chief Executive Officer chez VBI VACCINES INC.
Fortune : 12 225 $ au 31/03/2024
Profil
M. Jeffrey R. Baxter est président, chef de la direction et directeur chez VBI Vaccines, Inc. et directeur non exécutif indépendant chez Chromadex Corp. et président, chef de la direction et directeur chez VBI Vaccines (Delaware), Inc. et président, chef de la direction et directeur chez Variation Biotechnologies (US), Inc. Il siège au conseil d'administration de VBI Vaccines, Inc. et de Chromadex Corp, de VBI Vaccines (Delaware), Inc. et de Variation Biotechnologies (US), Inc. Auparavant, M. Baxter a été employé comme SVP-Finance, Operations, Research & Development par GlaxoSmithKline Plc, comme directeur par British American Tobacco plc, comme associé directeur par The Column Group LLC, et comme directeur par Unilever Plc. Il a obtenu son diplôme de premier cycle à la Thames Valley University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
VBI VACCINES, INC.
0,09% | 27/07/2023 | 20 274 ( 0,09% ) | 12 225 $ | 31/03/2024 |
Postes actifs de Jeff Baxter
| Sociétés | Poste | Début |
|---|---|---|
| VBI VACCINES INC. | Chief Executive Officer | 01/05/2016 |
Variation Biotechnologies (US), Inc.
 Variation Biotechnologies (US), Inc. BiotechnologyHealth Technology Variation Biotechnologies (US), Inc. develops and manufactures vaccines for infectious diseases. It is dedicated to the innovative formulation, development and delivery of safe and effective vaccines that expand and enhance vaccine protection in both established and emerging markets. The company was founded by David E. Anderson and Adam Buckley in 2001 and is headquartered in Boston, MA. | Chief Executive Officer | 22/09/2009 |
VBI Vaccines (Delaware), Inc.
 VBI Vaccines (Delaware), Inc. BiotechnologyHealth Technology Part of VBI Vaccines, Inc., VBI Vaccines (Delaware), Inc. develops biopharmaceuticals. Jeffrey R. Baxter has been the CEO of the American company since 2014. | Chief Executive Officer | 01/07/2014 |
Anciens postes connus de Jeff Baxter
| Sociétés | Poste | Fin |
|---|---|---|
| CHROMADEX CORPORATION | Director/Board Member | 04/04/2022 |
The Column Group LLC
 The Column Group LLC Investment ManagersFinance The Column Group LLC is a venture capital firm founded in 2005 by Peter Svennilson. The firm is headquartered in San Francisco. | Chief Investment Officer | 28/02/2009 |
| GSK PLC | Corporate Officer/Principal | 01/07/2006 |
| UNILEVER PLC | Corporate Officer/Principal | - |
| BRITISH AMERICAN TOBACCO P.L.C. | Corporate Officer/Principal | - |
Formation de Jeff Baxter
| University of West London | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| BRITISH AMERICAN TOBACCO P.L.C. | Consumer Non-Durables |
| UNILEVER PLC | Consumer Non-Durables |
| GSK PLC | Health Technology |
| CHROMADEX CORPORATION | Health Technology |
| VBI VACCINES INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Variation Biotechnologies (US), Inc.
Variation Biotechnologies (US), Inc. BiotechnologyHealth Technology Variation Biotechnologies (US), Inc. develops and manufactures vaccines for infectious diseases. It is dedicated to the innovative formulation, development and delivery of safe and effective vaccines that expand and enhance vaccine protection in both established and emerging markets. The company was founded by David E. Anderson and Adam Buckley in 2001 and is headquartered in Boston, MA. | Health Technology |
The Column Group LLC
The Column Group LLC Investment ManagersFinance The Column Group LLC is a venture capital firm founded in 2005 by Peter Svennilson. The firm is headquartered in San Francisco. | Finance |
VBI Vaccines (Delaware), Inc.
VBI Vaccines (Delaware), Inc. BiotechnologyHealth Technology Part of VBI Vaccines, Inc., VBI Vaccines (Delaware), Inc. develops biopharmaceuticals. Jeffrey R. Baxter has been the CEO of the American company since 2014. | Health Technology |
